Intra-Cellular Therapies Inc

NASDAQ:ITCI  
58.28
-0.44 (-0.75%)
Earnings Announcements

Intra-Cellular Therapies Reports First Quarter 2022 Financial Results And Provides Corporate Update

Published: 05/10/2022 11:38 GMT
Intra-Cellular Therapies Inc (ITCI) - Intra-cellular Therapies Reports First Quarter 2022 Financial Results and Provides Corporate Update.
Q1 Revenue Rose 120 Percent to $35 Million.
Qtrly Net Loss per Common Share Basic & Diluted $0.78.
Q1 Earnings per Share View $-0.92, Revenue View $33.7 Million -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $47.44 Million
Adjusted EPS is expected to be -$0.80

Next Quarter Revenue Guidance is expected to be $61.64 Million
Next Quarter EPS Guidance is expected to be -$0.73

More details on our Analysts Page.